FRI0200 Achievement of low disease activity (LDA) at 3 months predicts clinical remission (REM) at 1 year of infliximab (IFX) therapy in ra: post-hoc analysis of a randomized double-blind clinical study (rising study)

Abstract

BackgroundIn treatment of RA using TNF-inhibitors, switching to another treatment is recommended if a patient shows moderate or high disease activity (MDA, HDA) at 3 months (1). Meanwhile, dose-escalation of...